BioCentury | Mar 10, 2018
Product Development

Virtual leap

...trial, which was launched by Pfizer Inc. in 2011. Pfizer’s Phase IV REMOTE study of Detrol LA...
BioCentury | Jan 13, 2014
Company News

Teva, Pfizer sales and marketing update

...Teva launched an authorized generic of Pfizer's Detrol LA tolterodine ER in the U.S. Detrol LA, an extended-release muscarinic...
...frequency. Teva declined to disclose the price of the generic. Pfizer reported combined Detrol and Detrol LA...
...the nine months ended Sept. 30, 2013; the pharma does not break out sales for Detrol LA...
BioCentury | Dec 16, 2013
Strategy

Out in the cold

...buprenorphine/naloxone Reckitt Benckiser/MonoSol Rx CVS Immunosuppressants, calcineurin inhibitors(transplant) Hecoria tacrolimus Novartis CVS Urinary antispasmodics (OAB/incontinence) Detrol LA...
BioCentury | Sep 17, 2012
Company News

Mylan, Pfizer genitourinary news

...Jersey claiming that Mylan's ANDA for a generic version of Pfizer's overactive bladder (OAB) drug Detrol LA...
...earlier under undisclosed circumstances, and March 1, 2014, pending approval. The basic product patent for Detrol LA...
...the formulation patents expire in December 2020. The companies declined to disclose details. Pfizer markets Detrol LA...
BioCentury | Aug 13, 2012
Clinical News

Toviaz fesoterodine: Phase IV data

...Phase IV trial in 642 patients with OAB who had a suboptimal response to Detrol LA tolterodine ER...
...to initially receive open-label, once-daily Detrol LA for 2 weeks. Patients with a suboptimal response to Detrol LA...
...rights to Toviaz from Schwarz Pharma AG , now part of UCB. Pfizer also markets Detrol LA...
BioCentury | Jul 16, 2012
Clinical News

Detrol LA tolterodine ER: Phase IV discontinued

...discontinued enrollment in the double-blind, placebo-controlled, U.S. Phase IV REMOTE trial evaluating daily 4 mg Detrol LA...
...by replicating the results of a previously completed 8-week, double-blind, European Phase IV trial of Detrol LA...
...urge urinary incontinence, urgency and frequency. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Detrol LA tolterodine ER (Detrol LA...
BioCentury | Jun 27, 2011
Clinical News

Detrol LA tolterodine ER: Phase IV started

...began the double-blind, placebo-controlled, U.S. Phase IV REMOTE trial to evaluate daily 4 mg Detrol LA tolterodine ER...
...by replicating the results of a previously completed 8-week, double-blind, European Phase IV trial of Detrol LA...
...of urge urinary incontinence, urgency and frequency. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Detrol LA tolterodine ER...
BioCentury | May 23, 2011
Clinical News

THVD-201: Phase II started

...Phase II trial in 120 female patients to compare 2 mg THVD-201 vs. 2 mg Detrol LA...
...in an open-label extension period after 16 weeks. Pfizer Inc. (NYSE:PFE, New York, N.Y.) markets Detrol LA...
BioCentury | Apr 4, 2011
Clinical News

THVD-201: Phase I data

...THVD-201 was safe and improved salivary output and related dry mouth side effects compared to Detrol LA...
BioCentury | May 4, 2009
Clinical News

Detrol LA tolterodine ER: Post-marketing study data

...in 32% of females and 35% of males. Branded drugs included in the study were Detrol LA...
...U.K. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Detrol LA tolterodine ER...
Items per page:
1 - 10 of 25